TrialDiabetes, obesity & metabolism2019

Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.

Silvina Gallo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.